Sanofi (SNY) Receives “Neutral” Rating from JPMorgan Chase & Co.

Share on StockTwits

Sanofi (NYSE:SNY)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Monday.

SNY has been the topic of a number of other research reports. Jefferies Financial Group upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, December 11th. Wolfe Research began coverage on shares of Sanofi in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Zacks Investment Research lowered shares of Sanofi from a “hold” rating to a “sell” rating in a report on Tuesday, October 16th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Friday, November 30th. Finally, Argus lifted their price target on shares of Sanofi from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $50.00.

NYSE SNY opened at $42.44 on Monday. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The company has a market cap of $108.88 billion, a P/E ratio of 13.56, a PEG ratio of 2.41 and a beta of 0.67. Sanofi has a 1 year low of $37.43 and a 1 year high of $45.86.

Sanofi (NYSE:SNY) last posted its quarterly earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.09. The business had revenue of $9.39 billion for the quarter, compared to analyst estimates of $9.10 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the business posted $1.71 EPS. Equities analysts expect that Sanofi will post 3.1 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Visionary Asset Management Inc. increased its stake in Sanofi by 2.8% in the fourth quarter. Visionary Asset Management Inc. now owns 11,342 shares of the company’s stock valued at $492,000 after purchasing an additional 314 shares in the last quarter. CENTRAL TRUST Co increased its stake in Sanofi by 7.7% in the fourth quarter. CENTRAL TRUST Co now owns 4,925 shares of the company’s stock valued at $213,000 after purchasing an additional 350 shares in the last quarter. Moody National Bank Trust Division increased its stake in Sanofi by 1.3% in the fourth quarter. Moody National Bank Trust Division now owns 36,046 shares of the company’s stock valued at $1,565,000 after purchasing an additional 446 shares in the last quarter. Rehmann Capital Advisory Group increased its stake in Sanofi by 14.8% in the third quarter. Rehmann Capital Advisory Group now owns 5,950 shares of the company’s stock valued at $266,000 after purchasing an additional 766 shares in the last quarter. Finally, Wealthstreet Investment Advisors LLC increased its stake in Sanofi by 14.3% in the third quarter. Wealthstreet Investment Advisors LLC now owns 10,392 shares of the company’s stock valued at $464,000 after purchasing an additional 1,300 shares in the last quarter. 7.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Leveraged Buyout (LBO)

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.